$AYLA

Ayala Pharmaceuticals Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

PRICE

$1.09 ▼-2.031%

Last Close

VOLUME

8,816

DAY RANGE

1.06 - 1.15

52 WEEK

0.9562 - 14.95

Join Discuss about AYLA with like-minded investors

profile
@dros #droscrew
recently

+Initiations 12/20: $ASML $AYLA $BCDA $BEAT $CCB $CMPX $CNNE $CRWD $CTOS $EDSA $ETNB $FNV $NOK $PRPH $SOFI $STM . -Initiations 12/20:

118 Replies 14 👍 8 🔥

profile
@dros #droscrew
recently

Upgrades 11/30: $AYLA $BXMT $CAJ $ESMT $HHR $KRP $MAG $PTR $SQ $TTE $ZM . Downgrades 11/30: $ABEO $CENT $CGC $CQP $DLTR $FLMN $GDP $SEDG $SGTX $STNE $STXB $TROX $VG

145 Replies 13 👍 7 🔥

profile
@dros #droscrew
recently

$AYLA - 442k share Dark Pool print @ 14

96 Replies 9 👍 7 🔥

profile
@dros #droscrew
recently

Initiations 12/7: $AXP $AYLA $CNXC $FIS $GRTX $IMAB $MA $MATN $PHGE $PRTA $SQ $TFFP $V

70 Replies 7 👍 12 🔥

Key Metrics

Market Cap

15.35 M

Beta

0.03

Avg. Volume

24.38 K

Shares Outstanding

14.09 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-11

Next Dividend Date

Company Information

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE).

Website:

HQ: ,

Related News